VRTX
HealthcareVertex Pharmaceuticals
Price Chart
Market Data
Financials
XBRL · SEC EDGAR2008–2025(18yr)| Metric | FY 2008 | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025Latest | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $175.5M | $101.9M | $143.4M | $1.4B | $1.5B | $1.2B | $580.4M | $1.0B | $1.7B | $2.5B | $3.0B | $4.2B | $6.2B | $7.6B | $8.9B | $9.9B | $11.0B | $12.0B | +8.9% |
| Gross Profit | — | — | $143.4M | $1.3B | $1.3B | $1.1B | $540.7M | $915.2M | $1.5B | $2.2B | $2.6B | $3.6B | $5.5B | $6.7B | $7.9B | $8.6B | $9.5B | $10.3B | +9.1% |
| Gross Margin | — | — | 100.0% | 95.5% | 84.5% | 92.7% | 93.2% | 88.7% | 87.6% | 88.9% | 86.6% | 86.8% | 88.1% | 88.1% | 87.9% | 87.2% | 86.1% | 86.2% | +0.1pp |
| Operating Income | -$462.7M | -$614.0M | -$696.1M | $113.8M | $2.3M | -$903.4M | -$692.4M | -$466.9M | $9.9M | $123.2M | $635.1M | $1.2B | $2.9B | $2.8B | $4.3B | $3.8B | -$232.9M | $4.2B | +1891.9% |
| Operating Margin | -263.6% | -602.6% | -485.5% | 8.1% | 0.2% | -74.5% | -119.3% | -45.2% | 0.6% | 5.0% | 20.8% | 28.8% | 46.0% | 36.7% | 48.2% | 38.8% | -2.1% | 34.8% | +36.9pp |
| Net Income | -$459.9M | -$642.2M | -$754.6M | $29.6M | -$107.0M | -$445.0M | -$738.6M | -$556.3M | -$112.1M | $263.5M | $2.1B | $1.2B | $2.7B | $2.3B | $3.3B | $3.6B | -$535.6M | $4.0B | +838.1% |
| Net Margin | -262.0% | -630.3% | -526.3% | 2.1% | -7.0% | -36.7% | -127.2% | -53.9% | -6.6% | 10.6% | 68.8% | 28.3% | 43.7% | 30.9% | 37.2% | 36.7% | -4.9% | 32.9% | +37.8pp |
| Free Cash Flow | -$258.7M | -$451.1M | -$673.5M | $109.1M | $196.7M | -$103.0M | -$564.4M | -$410.7M | $179.5M | $745.5M | $1.2B | $1.5B | $3.0B | $2.4B | $3.9B | $3.3B | -$790.3M | $3.2B | +504.1% |
| FCF Margin | -147.4% | -442.7% | -469.8% | 7.7% | 12.9% | -8.5% | -97.2% | -39.8% | 10.5% | 30.0% | 38.5% | 35.9% | 48.2% | 31.8% | 44.0% | 33.8% | -7.2% | 26.6% | +33.8pp |
| EPS (Diluted) | $-3.27 | $-3.71 | $-3.77 | $0.14 | $-0.50 | $-1.98 | $-3.14 | $-2.31 | $-0.46 | $1.04 | $8.09 | $4.51 | $10.29 | $9.01 | $12.82 | $13.89 | $-2.08 | $15.32 | +836.5% |
1. THE BIG PICTURE
Vertex Pharmaceuticals is currently a "cash cow" in transition, leveraging its near-total dominance of the cystic fibrosis (CF) market to fund an aggressive expansion into acute pain and gene editing. While Vertex Pharmaceuticals maintains the highest profit margins among its peers, its long-term valuation depends entirely on whether its "serial innovation" strategy can replicate its CF success in new, more operationally complex disease areas.
2. WHERE THE RISKS HIT HARDEST
Vertex Pharmaceuticals’s "strong financial profile" (Competitive Position) is directly threatened by its "concentration of revenue" (Risks) because substantially all net product revenues are derived from CF medicines. Any decline in these sales would jeopardize the capital necessary to fund the "serial innovation" strategy that defines its business model. Furthermore, the "best-in-class" efficacy of the new gene-editing therapy CASGEVY is undermined by its "complex infrastructure" and manufacturing costs, which significantly exceed those of CF medicines as a percentage of revenue (Risks). This complexity threatens to dilute the industry-leading margins that currently justify the stock's premium valuation.
3. WHAT THE NUMBERS SAY TOGETHER
Vertex operates with exceptional efficiency, boasting a peer-leading 86.4% gross margin and 32.9% net margin (Peer Benchmarking). However, its +8.9% revenue growth trails significantly behind faster-growing peers like Eli Lilly (+44.7%). This divergence highlights a business that has mastered its current niche but has yet to see its newer ventures reach commercial velocity. Management’s 2026 guidance anticipates $500 million or more in non-CF revenue (8-K), which represents less than 4% of the projected $13 billion total revenue. This confirms that despite the launch of CASGEVY and JOURNAVX, Vertex Pharmaceuticals remains structurally tethered to its CF franchise for the foreseeable future. Vertex is using its $4.8 billion net cash position to return value via a 1.8% buyback yield—the highest in its peer group—acting as a buffer while the market waits for the pipeline to diversify the top line.
4. IS IT WORTH IT AT THIS PRICE?
At 22.8x Forward P/EP/EPrice-to-Earnings ratio — share price divided by annual earnings per share; how much investors pay per dollar of profit. Higher P/E = higher growth expectations, Vertex trades at a 41% premium to the peer median of 16.1x (Peer Benchmarking). This premium is supported by Vertex Pharmaceuticals’s superior FCFFCFFree Cash Flow — cash left after paying for operations and capital investments; what the company can actually spend, save, or return to shareholders margin (35.8%) and its dominant competitive position, with its CF medicines used by "nearly three quarters" of the eligible population (Competitive Position). At this multiple, the market is pricing in ~1.9% long-term growth (CAPM analysis). This appears conservative given Vertex Pharmaceuticals’s +8.9% TTMTTMTrailing Twelve Months — the most recent full year of financial data, updated on a rolling basis each quarter revenue growth and the "pipeline-in-a-product" potential of candidates like povetacicept. However, the valuation is sensitive to "pricing and reimbursement pressures" (Risks); if regulatory reviews or "most-favored-nation" pricing proposals cap the price of CF drugs, the implied growth rate would likely turn negative, triggering a sharp contraction in the P/EP/EPrice-to-Earnings ratio — share price divided by annual earnings per share; how much investors pay per dollar of profit. Higher P/E = higher growth expectations multiple.
5. WHAT WOULD CHANGE THIS VIEW?
- Constructive if non-CF revenue in 2026 significantly exceeds the $500 million guidance, proving that JOURNAVX and CASGEVY can scale without eroding corporate margins (8-K).
- Cautious if combined GAAPGAAPGenerally Accepted Accounting Principles — the standard U.S. accounting rules all public companies must follow R&DR&DResearch & Development — spending on creating new products or technologies and SG&ASG&ASelling, General & Administrative expenses — operating costs not directly tied to making the product: salaries, marketing, rent, etc. expenses exceed the $6.45 billion guidance without a corresponding increase in the "nearly three quarters" CF market share, indicating rising costs to defend a maturing market (8-K).
- Cautious if the "complex infrastructure" required for CASGEVY leads to slower-than-expected patient uptake at authorized treatment centers (Competitive Position).
6. BOTTOM LINE
Structural Advantage: A dominant, high-margin monopoly in cystic fibrosis that generates massive free cash flow to self-fund a diverse pipeline of first-in-class therapies.
Bottom Line: Vertex is a highly profitable defensive play with significant upside if it can prove its "serial innovation" works outside of its core CF franchise.
1. Top 5 Material Risks
- Concentration of Revenue: Substantially all net product revenues are derived from CF medicines. Any failure to sustain or increase these sales, whether due to competition or an inability to reach patients who cannot benefit from current treatments, would materially harm the business and its ability to fund operations.
- CASGEVY Profitability: The manufacturing and administration of CASGEVY are more resource-intensive and complex than small-molecule CF medicines. The cost of manufacturing CASGEVY as a percentage of revenue is significantly higher, creating a risk that Vertex Pharmaceuticals may not be able to maintain or increase revenues from this product.
- Pricing and Reimbursement Pressures: Third-party payors, including government programs and commercial insurers, are increasingly focused on cost containment. Initiatives such as the U.S. government’s "most-favored-nation" pricing proposals or the Colorado PDAB’s affordability reviews could limit the prices of, or access to, Vertex Pharmaceuticals products.
- Clinical Development Uncertainty: Product development is expensive and highly uncertain. Vertex Pharmaceuticals has previously experienced failures, such as the VX-264 program in T1D, which did not meet its efficacy endpoint, leading to the cessation of development activities and the inability to recoup significant research and development expenses.
- Competitive Landscape: Vertex Pharmaceuticals faces competition from companies with greater resources and more mature organizations. If a competitor obtains approval and reimbursement first, or if a competing product is more effective or lower-priced, Vertex Pharmaceuticals’s market position and revenues could be materially adversely affected.
2. Company-Specific Risks
- Product Liability and Safety: Because Vertex Pharmaceuticals products are used by larger populations post-approval, previously unknown safety issues may emerge. For example, the FDA required a "boxed warning" for TRIKAFTA and ALYFTREK regarding liver injury, which could negatively affect commercial sales and market acceptance.
- Intellectual Property Disputes: Vertex Pharmaceuticals is currently involved in arbitration initiated by a third party regarding ALYFTREK royalty rights. An adverse outcome could result in higher future costs of goods if royalty fees are determined to be higher than anticipated.
- Geopolitical Supply Chain Exposure: Vertex Pharmaceuticals depends on China-based suppliers for portions of its supply chain. Geopolitical developments or U.S. legislation limiting the use of Chinese biotechnology services could force Vertex Pharmaceuticals to find alternative suppliers, which may not be feasible or could involve significant time and expense.
- Facility Concentration: Most research and development activities are conducted in a limited number of facilities, including corporate headquarters and laboratory space located in a flood zone along the Massachusetts coast. A catastrophic event at these sites could cause a significant disruption in operations.
3. Regulatory/Legal Risks
- Marketing and Promotional Compliance: Vertex Pharmaceuticals is subject to strict laws regulating promotional activities. If regulators interpret marketing practices as promotion of unapproved uses, Vertex Pharmaceuticals could face enforcement actions, including warning letters, seizure of products, and significant civil or criminal fines.
- Data Privacy and Security: Vertex Pharmaceuticals is subject to evolving global data privacy laws, such as the GDPR and the California Consumer Privacy Act. The commercialization of cell and genetic therapies involves processing more personal data than traditional therapies, increasing Vertex Pharmaceuticals's risk exposure to government enforcement and private litigation.
- Government Price Reporting: Methodologies for calculating and reporting pricing to government agencies are subject to assumptions that may be challenged. If the government disagrees with these calculations, Vertex Pharmaceuticals may be required to restate previously reported data and could face additional financial and legal liability.
4. Financial Impact Map
Concentration of CF Revenue → Net Product Revenues → Substantially all revenue is derived from this single therapeutic area. CASGEVY Manufacturing Costs → Cost of Goods Sold / Gross Margin → Manufacturing costs as a percentage of revenue are significantly higher than for CF medicines. Pricing and Reimbursement Pressures → Net Product Revenues → Potential for reduced pricing, restricted access, or exclusion from formularies. Clinical Development Failures → Research and Development Expenses → Significant expenses incurred for programs that may not reach commercial success or may be terminated. ALYFTREK Royalty Arbitration → Cost of Goods Sold → Potential for higher future royalty payments if the arbitration outcome is unfavorable.
Recent Filings
| Form | Filed | Period |
|---|---|---|
| 10-K | Feb 2026 | Dec 2025 |
| 8-K | Feb 2026 | — |
| 10-Q | Nov 2025 | Sep 2025 |
| 14A | Apr 2025 | — |
AI-extracted key facts from press releases and SEC filings. Significance 1–10.
VRTX Q1 EPS $4.47 beats $4.23 estimate, revenue $2.99B rises 8% YoY
- ▸Q1 adjusted EPS $4.47, beating consensus estimate of $4.23
- ▸Total revenue $2.99B, up 8% YoY, slightly exceeding $2.98B estimate
- ▸Trikafta sales $2.35B, down 7.5% YoY and missing $2.39B estimate
- ▸Journavx sales reached $29M, up from $26.7M in Q4
- ▸Reiterated full-year 2026 revenue guidance of $12.95B–$13.10B
Vertex Pharmaceuticals Raises Fair Value Estimate to $547.72 Following Positive Povetacicept Phase 3 Data
- ▸Povetacicept RAINIER Phase 3 data shows 52% reduction in urine protein to creatinine ratio
- ▸Serum Gd-IgA1 levels reduced by 77.4% in IgA nephropathy patients
- ▸BLA filing for povetacicept expected by end of March using priority review voucher
- ▸FY2026 revenue guidance $12.95B–$13.1B, including $500M+ from non-cystic fibrosis products
- ▸Multiple analysts raise price targets to $525–$641 range following pipeline de-risking
Vertex Phase 3 RAINIER Data Shows Significant Proteinuria Reduction; Rolling BLA Underway
- ▸Phase 3 RAINIER interim data shows statistically significant proteinuria and biomarker reduction
- ▸Povetacicept rolling BLA underway with FDA using priority review voucher
- ▸Breakthrough Therapy Designation granted for povetacicept in IgA nephropathy
- ▸Company targeting diversification beyond cystic fibrosis into kidney disease portfolio
- ▸Projected 2029 revenue $16.0B with $5.9B earnings target
Vertex Pharmaceuticals reports positive Phase 3 RAINIER results, initiates rolling BLA for povetacicept
- ▸Phase 3 RAINIER trial shows clinically meaningful proteinuria reductions in IgA nephropathy
- ▸Initiated rolling Biologics License Application using priority review voucher
- ▸Povetacicept development signals expansion beyond core cystic fibrosis franchise
- ▸Current revenue remains heavily concentrated in $12B annual cystic fibrosis segment
- ▸New diversified portfolio includes CASGEVY, JOURNAVX, and renal pipeline
Vertex Pharmaceuticals Q4 revenue $3.19B +9.5% YoY, misses EPS estimates
- ▸Vertex Q4 revenue $3.19B, up 9.5% YoY, beat estimates by 1.1%
- ▸Vertex Q4 EPS missed analyst consensus expectations
- ▸Novavax Q4 revenue $147.1M, up 66.6% YoY, beat estimates by 57.4%
- ▸Therapeutics sector Q4 revenues beat consensus estimates by 7.1% on average
- ▸Novavax stock rose 11.3% following Q4 earnings report
Saudi Aramco CEO warns Iran conflict poses catastrophic risk to global oil markets
- ▸Strait of Hormuz closure threatens 20% of daily global oil supply
- ▸Brent crude reached three-year high of nearly $120 per barrel
- ▸ExxonMobil earnings sensitivity estimated at $2B per $10/barrel oil price increase
- ▸ExxonMobil 2025 production reached 4.7 million oil-equivalent barrels per day
- ▸Oil shocks act as economic tax impacting aviation, agriculture, and manufacturing sectors
Vertex Phase III RAINER study shows 52% proteinuria reduction for IgAN drug povetacicept
- ▸Povetacicept achieved 52% reduction in proteinuria at 36 weeks in phase III RAINER study
- ▸Drug outperformed placebo by 49.8% in primary endpoint analysis
- ▸RAINER study met all secondary endpoints with favorable safety and tolerability profile
- ▸Upcoming quarterly earnings expected at $4.47 EPS, +10.1% YoY
- ▸Projected quarterly revenue $3.05B, +10.1% YoY
Multiple Companies Report Q4/Q3 Earnings Results and Clinical Trial Updates
- ▸KSS Q4 revenue $5.17B, missed consensus estimate of $5.23B
- ▸UNFI Q2 revenue $7.95B, missed consensus estimate of $8.15B
- ▸CASY Q3 EPS $3.49, beat consensus estimate of $3.01
- ▸VRTX drug met primary endpoints in late-stage IgA nephropathy clinical trial
- ▸VRTX shares rose 8.3% following positive clinical trial results